Table 1.

Description of the ankylosing spondylitis population.

VariableMean ± SDRange
Age, yrs45.4 ± 11.826–75
Men:women ratio31:12
Age at diagnosis, yrs32.8 ± 10.516–57
BMI, kg/m225.0 ± 3.819–33
Disease duration, yrs13.2 ± 10.62–40
Axial:peripheral ratio33:10
ESR, mm/h15.5 ± 15.62–68
CRP, mg/l9.00 ± 11.50.5–56.7
HLA-B27 positivity, %83.7
Current smokers, %30.2
Pain on VAS, mm51.1 ± 31.912–90
Disease activity on VAS, mm49.7 ± 28.58–93
Active disease (% BASDAI > 40)32.6
BASDAI, mm50.4 ± 19.119–80
BASFI45.4 ± 11.8
BASMI45.4 ± 11.8
Lumbar spine mobility; Schober, cm2.2 ± 1.70.5–5.5
Chest expansion, cm2.3 ± 1.21.1–4.5
Wall-occiput distance, cm8.2 ± 8.50–22
Current NSAID therapy, %86
Current DMARD therapy, %14
Current anti-TNF therapy, %65
  • BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analog scale; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; BASMI: Bath AS Metrology Index; NSAID: nonsteroidal antiinflammatory drug; DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.